FARNBOROUGH, England, July 18, 2022 - Pratt & Whitney is modernizing and transforming its Operations business with Industry 4.0 technologies in the pursuit of unbeatable. | July 18, 2022
- Brilaroxazine is a novel serotonin and dopamine receptor modulator currently being developed for diseases with dysfunctional serotonin signaling including neuropsychiatric and pulmonary indications.
Want a fast USB-C wall charger that doesn’t look or feel like a brick? Then perhaps Cirtek’s 20W USB-C charger could be what you were looking for, where it offers up fast charging speeds in a charger that could easily slip into your pocket.
Reviva Pharmaceuticals : Reports Second Quarter 2021 Financial Results and Recent Business Highlights marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Share:
Schizophrenia is the most common psychotic disease with a global prevalence in about 1% of the population, affecting approximately 3.5 million people in the U.S. and 20 million globally. Despite the high prevalence, there is currently no therapy that adequately addresses the complex mental disorder.
Current antipsychotics prescribed for schizophrenia are plagued with suboptimal efficacy, poor tolerability, adverse effects and abnormally high dropout rates.
As a result of suboptimal efficacy, the major symptoms of schizophrenia, such as chronic mood symptoms and cognitive dysfunction, are not adequately addressed to date. In addition, approved antipsychotics are reported to cause adverse effects at varying degrees including extrapyramidal symptoms (EPS), akathisia, obesity, diabetes, cholesterol and sexual dysfunction.